Sources and Clinical References

These are the core references behind our guides. Each guide also lists the specific sources it uses at the end of the page.

Trial publications

• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine, 2023. 338 adults, 48 weeks.

Company announcements

• Eli Lilly and Company. TRIUMPH-4 topline results, December 2025.
• Eli Lilly and Company. TRIUMPH-1 topline results, 2026.
• Eli Lilly and Company. What to know about retatrutide.

Trial registrations

• ClinicalTrials.gov search for retatrutide, where every registered retatrutide study, including the TRIUMPH and TRANSCEND programs, is listed with its status.

Regulators

• US Food and Drug Administration, European Medicines Agency and UK Medicines and Healthcare products Regulatory Agency for approval status and safety communications.